Riskpilot← Back to searchSign inGet full accessCloneOpt AB
ABActiveOrg 5569945883Svante Arrhenius Väg 16 CManufacture of pharmaceutical preparations · NACE 2120Est. 20141 employees
Revenue 2025
SEK 563K
0% vs 2024
EBITDA margin
-1.8%
-109% vs 2024
Equity ratio
81.5%
Financial strength
Net profit 2025
SEK -5K
-108% vs 2024
| Revenue | SEK 563K | +0% |
| EBITDA | SEK -10K | -109% |
| Net profit | SEK -5K | -108% |
| Total assets | SEK 1,2M | -18% |
| Equity | SEK 977K | -18% |
| Employees | 1 | — |
Legal name
CloneOpt AB
Org number
5569945883
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
9 december 2014
Share capital
SEK 51 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-05-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva forsknings- och utvecklingsarbete kring proteinproduktion och försäljning av proteiner och därmed förenlig verksamhet.
Address
Svante Arrhenius Väg 16 C
Email
ddaley@dbb.su.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 625 | 1 064 | 812 | 563 | 563 |
| Staff expenses | — | −0 | — | — | −0 |
| EBITDA | −169 | 433 | 386 | 119 | −10 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −169 | 433 | 386 | 119 | −10 |
| Net financials | −2 | — | −1 | −4 | −2 |
| Profit before tax | −8 | 325 | 385 | 85 | −5 |
| Tax | −0 | −67 | −80 | −19 | −0 |
| Net profit | −8 | 258 | 305 | 66 | −5 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 141 | 1 578 | 1 669 | 1 470 | 1 199 |
| Equity | 1 124 | 1 198 | 1 315 | 1 186 | 977 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 10 | 264 | 238 | 139 | 84 |
| Total debt | 10 | 264 | 238 | 139 | 84 |
EBITDA margin
-1.8%
This company
15.8%
Market median
-111% vs market
20212025
Equity ratio
81.5%
This company
38.2%
Market median
+113% vs market
20212025
Return on equity
-0.5%
This company
18.4%
Market median
-103% vs market
20212025
Net profit margin
-0.9%
This company
8.1%
Market median
-111% vs market
20212025
Asset turnover
0.47×
This company
1.12×
Market median
-58% vs market
20212025
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-06-01 – 2025-05-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-06-01 – 2024-05-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-06-01 – 2021-05-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CloneOpt AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kiavash Mirzadeh | Deputy Chief Executive Officer | 0 companies |
| Daniel Oliver Daley | Chairman | 0 companies |
| Morten Helge Hauberg Nörholm | Board of Directors | 0 companies |